…another stock I have in my portfolio – this one already performing well – is Thrombogenics, a biopharmaceutical company focused on developing and commercialising innovative ophthalmic medicines (that’s the spiel), and based in Belgium. Earlier this year Thrombogenics announced that theirMicroplasmin Meets Primary Endpoint in Phase III Trial for the Non-SurgicalTreatment of Symptomatic Vitreomacular Adhesion (VMA). In other words market their Microplasmin product has received the green light - and that’s why I am backing them.

The shares are listed on the Eurolist by Euronext Brussels under the symbol THR and are currently trading (21 Sept 2012) at €30.11, which is 35% up on when I bought them almost a year ago.

They’re worth backing in my view.

Please note: The views and opinions in this post are my own and should not constitute advice to purchase the stocks quoted.


Popular posts from this blog

The Estate of my great uncle, James Osenton the gold miner: the story continues...

Short Story: 'Nothing Left'